HC Wainwright Reiterates Buy Rating for Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (NASDAQ:CLDX)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report issued on Tuesday.
Other research analysts have also issued research reports about the stock. Cantor Fitzgerald restated a “buy” rating and set a $9.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, September 26th. Zacks Investment Research upgraded shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Tuesday, July 11th. ValuEngine lowered shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Finally, BidaskClub lowered shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $6.45.
Shares of Celldex Therapeutics (NASDAQ:CLDX) traded down $0.02 on Tuesday, hitting $2.73. 1,558,294 shares of the stock traded hands, compared to its average volume of 1,510,000. Celldex Therapeutics has a 52 week low of $2.20 and a 52 week high of $5.02.
Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.07. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 45.56%. The company had revenue of $3.90 million for the quarter, compared to analyst estimates of $1.30 million. During the same quarter in the prior year, the business posted ($0.29) EPS. Celldex Therapeutics’s quarterly revenue was up 77.3% on a year-over-year basis. research analysts forecast that Celldex Therapeutics will post -1.03 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “HC Wainwright Reiterates Buy Rating for Celldex Therapeutics, Inc. (CLDX)” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/11/09/hc-wainwright-reiterates-buy-rating-for-celldex-therapeutics-inc-cldx.html.
A number of large investors have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd acquired a new position in Celldex Therapeutics in the 3rd quarter valued at $242,000. Ameriprise Financial Inc. grew its stake in Celldex Therapeutics by 15.6% in the 3rd quarter. Ameriprise Financial Inc. now owns 441,411 shares of the biopharmaceutical company’s stock valued at $1,263,000 after buying an additional 59,629 shares during the last quarter. Russell Investments Group Ltd. grew its stake in Celldex Therapeutics by 741.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 352,511 shares of the biopharmaceutical company’s stock valued at $1,008,000 after buying an additional 310,638 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Celldex Therapeutics by 3.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 622,430 shares of the biopharmaceutical company’s stock valued at $1,780,000 after buying an additional 21,905 shares during the last quarter. Finally, Meditor Group Ltd grew its stake in Celldex Therapeutics by 8.8% in the 3rd quarter. Meditor Group Ltd now owns 6,312,700 shares of the biopharmaceutical company’s stock valued at $18,054,000 after buying an additional 512,700 shares during the last quarter. Institutional investors and hedge funds own 55.98% of the company’s stock.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.